{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T21:35:00Z","timestamp":1769722500527,"version":"3.49.0"},"reference-count":21,"publisher":"BMJ","issue":"7","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2019,7,1]]},"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:p>A man in his 70s with known systemic lupus erythematosus (SLE) was admitted with confusion, worsening proteinuria and cutaneous vasculitis despite adherence to his home immunosuppressive regimen. Admission laboratories were consistent with active lupus. Despite treatment with pulse\u2013dose glucocorticoids and intravenous immunoglobulin, he developed worsening mental status and meningeal signs. Investigations revealed cerebrospinal fluid (CSF) neutrophilic and plasmacytic pleocytosis and negative cultures. Empiric treatment for SLE flare with potential neuropsychiatric involvement was continued while workup for altered mental status was ongoing. Ultimately, West Nile encephalitis was diagnosed by CSF serologies, and steroids were tapered. Altered mental status in a patient with SLE has a broad differential, and primary neuropsychiatric SLE should be considered only after exclusion of secondary causes. Although evidence of end-organ SLE activity usually lends support to a neuropsychiatric SLE diagnosis, in this case, serological and clinical evidence of SLE activity may have been triggered by acute viral infection.<\/jats:p>","DOI":"10.1136\/bcr-2019-229537","type":"journal-article","created":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T07:25:20Z","timestamp":1564039520000},"page":"e229537","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["West Nile encephalitis mimicking neuropsychiatric lupus in a patient with systemic lupus erythematosus"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5557-7988","authenticated-orcid":false,"given":"Neena R","family":"Iyer","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W Joseph","family":"McCune","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Rheumatology, University of Michigan Medical School, Ann Arbor, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth I","family":"Wallace","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Rheumatology, University of Michigan Medical School, Ann Arbor, Michigan, USA"},{"name":"Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,7,24]]},"reference":[{"key":"2025082707124150000_12.7.e229537.1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199909)42:9<1785::AID-ANR1>3.0.CO;2-#"},{"key":"2025082707124150000_12.7.e229537.2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-F"},{"key":"2025082707124150000_12.7.e229537.3","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s40265-015-0534-3","article-title":"Management of neuropsychiatric systemic lupus erythematosus: current approaches and future perspectives","volume":"76","author":"Magro-Checa","year":"2016","journal-title":"Drugs"},{"key":"2025082707124150000_12.7.e229537.4","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1002\/art.39111","article-title":"Mood disorders in systemic lupus erythematosus: results from an international inception cohort study","volume":"67","author":"Hanly","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2025082707124150000_12.7.e229537.5","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.130476"},{"key":"2025082707124150000_12.7.e229537.6","first-page":"CD002265","article-title":"Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus","volume":"2","author":"Fernandes Mo\u00e7a Trevisani","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2025082707124150000_12.7.e229537.7","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2017-000253"},{"key":"2025082707124150000_12.7.e229537.8","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1985.00360100105017"},{"key":"2025082707124150000_12.7.e229537.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(99)80135-1"},{"key":"2025082707124150000_12.7.e229537.10","unstructured":"CDC. West Nile virus disease cases reported to ArboNET, United States. 1999 www.cdc.gov\/westnile\/resources\/pdfs\/data\/1999WNVHumanInfectionsbyState.pdf (Accessed 26 Dec 2018)."},{"key":"2025082707124150000_12.7.e229537.11","unstructured":"CDC. Preliminary west nile virus data for 2018. 2018 www.cdc.gov\/westnile\/statsmaps\/preliminarymapsdata2018\/index.html (Accessed 23 Jan 2018)."},{"key":"2025082707124150000_12.7.e229537.12","unstructured":"CDC. Arboviral diseases, neuroinvasive and non-neuroinvasive, case definition. 2015 www.cdc.gov\/nndss\/conditions\/arboviral-dises-neuroinvasive-and-non-neuroinvasive\/case-definition\/2015\/ (Accessed 26 Dec 2018)."},{"key":"2025082707124150000_12.7.e229537.13","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3122\/jabfm.17.6.470","article-title":"Cerebrospinal fluid neutrophilic pleocytosis in hospitalized West Nile virus patients","volume":"17","author":"Crichlow","year":"2004","journal-title":"J Am Board Fam Pract"},{"key":"2025082707124150000_12.7.e229537.14","doi-asserted-by":"publisher","DOI":"10.1002\/dc.20410"},{"key":"2025082707124150000_12.7.e229537.15","doi-asserted-by":"publisher","DOI":"10.1086\/375692"},{"key":"2025082707124150000_12.7.e229537.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2012.07.008"},{"key":"2025082707124150000_12.7.e229537.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2006.08.010"},{"key":"2025082707124150000_12.7.e229537.18","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.12.7466-7477.2005"},{"key":"2025082707124150000_12.7.e229537.19","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.000079"},{"key":"2025082707124150000_12.7.e229537.20","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4081\/cp.2012.e18","article-title":"The clinical response of West Nile virus neuroinvasive disease to intravenous immunoglobulin therapy","volume":"2","author":"Shimoni","year":"2012","journal-title":"Clin Pract"},{"key":"2025082707124150000_12.7.e229537.21","first-page":"151","article-title":"Hyperimmune gammaglobulin for the treatment of West Nile virus encephalitis","volume":"11","author":"Makhoul","year":"2009","journal-title":"Isr Med Assoc J"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2019-229537","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T14:12:50Z","timestamp":1756303970000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2019-229537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":21,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,7,24]]},"published-print":{"date-parts":[[2019,7]]}},"alternative-id":["10.1136\/bcr-2019-229537"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2019-229537","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7]]}}}